secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001193125-24-217619
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation
--------------------------------------------------------------------------------

- Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.
- Visual acuity preserved in 90% of 10 patients; 80% had high-risk tumors near fovea/optic disc.
- No treatment-related serious adverse events; mild Grade 1 ocular AEs self-limited, resolved in median 6 days.
- FDA agreed under Special Protocol Assessment for Phase 3 CoMpass trial; enrollment ongoing.
- Virtual investor event today at 8:00 am ET featuring key opinion leaders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/0001193125-24-217619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524217619/d886516d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer